Expert consensus on Injection of Breviscapine in clinical practice / 中国中药杂志
China Journal of Chinese Materia Medica
; (24): 2296-2299, 2020.
Article
in Zh
| WPRIM
| ID: wpr-827950
Responsible library:
WPRO
ABSTRACT
With the advancement of the aging process, cerebrovascular disease has become China's first cause of death. Injection of Breviscapine is a type of traditional Chinese medicine injections published in the Chinese Pharmacopoeia of 2015 Edition and the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue, and used to treat ischemic cerebrovascular disease in clinic. In order to further improve clinicians' understanding of the drug and guidance of its rational clinical use, we gave full consideration of clinical research evidences and expert experience, followed the procedures developed based on expert consensus of Chinese Academy of Traditional Chinese Medicine, and then offered recommendations for clinical problems summarized by clinical first-line investigations and evidence-based clinical problems according to internationally accepted evidence grading and recommendation standards, i.e. Grade. As for clinical problems without evidence, we reached through nominal group method, and formed consensus recommendations. Safety issues of Injection of Breviscapine, such as indication, syndrome, dosage, course of treatment, precautions, suggestions and contraindications, were defined to improve clinical efficacy, promote rational drug use and reduce drug risks. This consensus needs to be revised in the future based on emerging clinical issues and evidence-based updates in practical applications.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Flavonoids
/
Drugs, Chinese Herbal
/
China
/
Consensus
/
Medicine, Chinese Traditional
Type of study:
Diagnostic_studies
/
Guideline
Limits:
Female
/
Humans
/
Pregnancy
Country/Region as subject:
Asia
Language:
Zh
Journal:
China Journal of Chinese Materia Medica
Year:
2020
Type:
Article